Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RJVA-001 first-in-human pancreatic infusion study in adults with inadequately controlled type 2 diabetes
2025-524438-24-00Phase 2Authorised
- Sponsor
- Fractyl Health
- Start
- Sep 2026
- Modality
- Gene Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of RJVA-001 in type 2 diabetes mellitus (T2DM), sponsored by Fractyl Health. Primary endpoint: Incidence, severity, dose-relationship of adverse events and changes in laboratory evaluations. Planned start Sep 2026; status: authorised.
02
Drugs
RJVA-001
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2025-524438-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524438-24-00.